Publications by authors named "Dawn Brooks"

Claim this Profile
P
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Ming Lu, Min Jung Kim, Emily C Collins, Sergey Shcherbinin, Amy K Ellinwood, Dawn A Brooks

JAMA Neurol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.
Jennifer A Zimmer, John R Sims, Cynthia D Evans, Emel Serap Monkul Nery, Hong Wang, Dawn A Brooks

J Prev Alzheimers Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6.
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Dawn A Brooks

J Prev Alzheimers Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease.
Garrett R Mullins, Paul Ardayfio, Ivelina Gueorguieva, Greg Anglin, Jason Bailey, Dawn A Brooks

Alzheimers Dement (N Y)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab exposure-response in early symptomatic Alzheimer's disease.
Ivelina Gueorguieva, Kay Chow, Laiyi Chua, Sergey Shcherbinin, Jennifer A Zimmer, Dawn A Brooks

Alzheimers Dement· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.
Jennifer A Zimmer, Paul Ardayfio, Hong Wang, Rashna Khanna, Cynthia D Evans, Dawn A Brooks

JAMA Neurol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease.
Stephen Salloway, Andrew Pain, Elly Lee, Michelle Papka, Margaret B Ferguson, Dawn A Brooks

Alzheimers Dement· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Dawn A Brooks

Alzheimers Dement· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials.
Cynthia D Evans, JonDavid Sparks, Scott W Andersen, Dawn A Brooks, Paula M Hauck

Alzheimers Dement· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
John R Sims, Jennifer A Zimmer, Cynthia D Evans, Ming Lu, Paul Ardayfio, Dawn A Brooks

JAMA· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Sergey Shcherbinin, Cynthia D Evans, Ming Lu, Scott W Andersen, Michael J Pontecorvo, Dawn A Brooks

JAMA Neurol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Chafiq Hamdouchi, Steven D Kahl, Anjana Patel Lewis, Guemalli R Cardona, Richard W Zink, Dawn A Brooks

J Med Chem· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in Patient Screening Mammography Rates Associated With Internist Gender and Level of Training and Change Following the 2009 U.S. Preventive Services Task Force Guidelines.
Dawn J Brooks

J Natl Compr Canc Netw· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2014 AAHA weight management guidelines for dogs and cats.
Dawn Brooks, Julie Churchill, Karyn Fein, Deborah Linder, Kathryn E Michel

J Am Anim Hosp Assoc· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.
José A Martín, Dawn A Brooks, Lourdes Prieto, Rosario González, Alicia Torrado

Bioorg Med Chem Lett· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion of human-selective PPARalpha agonists to human/mouse dual agonists: a molecular modeling analysis.
Minmin Wang, Leonard L Winneroski, Robert J Ardecky, Robert E Babine, Dawn A Brooks

Bioorg Med Chem Lett· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.
Yanping Xu, Christopher J Rito, Garret J Etgen, Robert J Ardecky, James S Bean, Dawn A Brooks

J Med Chem· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of the Dakin-West reaction for the synthesis of oxazole-containing dual PPARalpha/gamma agonists.
Alexander G Godfrey, Dawn A Brooks, Lynne A Hay, Mary Peters, James R McCarthy

J Org Chem· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Greater GNN pattern bias in sequence elements encoding conserved residues of ancient proteins may be an indicator of amino acid composition of early proteins.
Dawn J Brooks, Jacques R Fresco

Gene· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of amino acid frequencies in proteins over deep time: inferred order of introduction of amino acids into the genetic code.
Dawn J Brooks, Jacques R Fresco, Arthur M Lesk, Mona Singh

Mol Biol Evol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Garret J Etgen, Brian A Oldham, William T Johnson, Carol L Broderick, Chahrzad R Montrose, Dawn A Brooks

Diabetes· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproducibility of control organism zone diameters for batches of IsoSensitest agar manufactured from 1996 to 2000 using the BSAC disc susceptibility test method.
Janine Landrygan, Peter A James, Dawn Brooks, Elizabeth M Kubiak

J Antimicrob Chemother· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased frequency of cysteine, tyrosine, and phenylalanine residues since the last universal ancestor.
Dawn J Brooks, Jacques R Fresco

Mol Cell Proteomics· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis